Jakafi 10 MG tablet 60S
Ended Awarded Last action
- Contract number
- SPE2DR26FMEF0
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $126,633
Award facts
- Contract value 100% obligated
- $126,632.70 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $126,632.70 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Jakafi 10 mg tablets (60-count units). This firm fixed-price delivery order, awarded on January 12, 2026, with an ultimate completion date of January 13, 2026, carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. The award was issued under DMS Pharmaceutical Group's existing Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy designed to establish multiple regional prime vendor contractors to supply comprehensive pharmaceutical products and medical consumables to Department of Defense healthcare facilities worldwide.
DMS Pharmaceutical Group has demonstrated substantial performance as a critical pharmaceutical supplier within the federal military medical supply chain since its registration in the System for Award Management in 2001. The company's portfolio encompasses branded and generic prescription medications, biologics, vaccines, specialty pharmaceuticals, and medical consumables spanning multiple therapeutic categories. Under the PPV-G GEN V contract awarded on November 13, 2025, with a $499,999,999 ceiling value and completion date of December 31, 2036, the contractor is positioned to fulfill diverse and specialized pharmaceutical requirements for Department of Defense healthcare operations globally through a structure featuring a 30-month base period with three 30-month option periods.
Quick answers
Who was awarded contract SPE2DR26FMEF0?
SPE2DR26FMEF0 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 12, 2026.
How much is contract SPE2DR26FMEF0 worth?
The government has obligated $126,633 on SPE2DR26FMEF0.
Is contract SPE2DR26FMEF0 an order under another contract?
Yes. SPE2DR26FMEF0 is a delivery order under SPE2DR25D9114, an indefinite delivery contract.
Was contract SPE2DR26FMEF0 competed?
The extent of competition for SPE2DR26FMEF0 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award